milar at €450 million-€500 million.
The strain is concentrated in green hydrogen. The company trimmed that unit’s sales outlook to €100 million-€130 million from €120 million-€170 million, while its Chlor-Alkali business (equipment used in chemical production) kept its outlook unchanged and order intake is still expected at €550 million-€670 million.
Zoom out, and the decision looks like a shift from “build it all in-house” ambition to tighter cost control. After higher hydrogen project costs and a terminated US pilot project, the company has already been cutting expenses, including a hiring freeze in higher-cost countries, and this move reinforces the message that scaling hydrogen gear is proving slower and more expensive than hoped.
Why should I care?
For markets: Thyssenkrupp Nucera’s €30 million SOEC write-down can shrink the hydrogen upside investors price in.
A €30 million EBIT hit that mainly reflects impairments is more than a messy quarter: it signals that some past spending is unlikely to deliver the cash flows once baked into longer-term forecasts. And by dropping plans for in-house, mass-scale SOEC stack production, Nucera is giving up some “option value” from vertical integration and scale manufacturing, which can limit future margin expansion and operating leverage if volumes ever ramp.
That matters because green hydrogen is the growth narrative, yet its sales outlook was cut to €100 million-€130 million. With that upside looking less open-ended, investors may lean more on what’s steadier: the unchanged Chlor-Alkali outlook and whether management can hit a now-wider fiscal 2026 loss range.
